Additionally, novel, transformative strategies in OI involve gene therapy to treat—or even prevent—OI symptomatology; advances in gene editing technologies have enabled the correction of COL1A1 and COL1A2 mutations. Here, COL1A2 is linked to osteogenesis imperfecta.